SCHEMBL10314647

SCHEMBL10314647

CN(CCO)C(=O)c1sc2c(c1OCc1ccncc1)c(=O)n(C)c1ccccc21

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.42
SGMS2 Q8NHU3 3/20 0.40
SGMS1 Q86VZ5 2/20 0.40
HDAC6 Q9UBN7 5/20 0.40
HDAC1 Q13547 4/20 0.40
HDAC8 Q9BY41 1/20 0.37
POLB P06746 1/20 0.37
ACKR3 P25106 1/20 0.37
HTR2C P28335 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MAPT P10636 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
KMT2A Q03164 1/20 0.34
KCNA5 P22460 1/20 0.34
MAPK14 Q16539 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10314611 0.93 TP53 (0.48) TP53SGMS2SGMS1HDAC6HDAC1
SCHEMBL10314377 0.92 TP53 (0.41) TP53SGMS2SGMS1HDAC6HDAC1
SCHEMBL10314389 0.91 KMT2A (0.42) TP53SGMS2SGMS1HDAC6HDAC1
SCHEMBL10314615 0.90 TP53 (0.43) TP53SGMS2SGMS1HDAC6HDAC1
SCHEMBL10314381 0.90 TP53 (0.55) TP53SGMS2SGMS1HDAC6HDAC1
SCHEMBL10314378 0.88 TP53 (0.41) TP53SGMS2SGMS1HDAC6HDAC1
SCHEMBL10314375 0.87 HDAC6 (0.41) TP53SGMS2SGMS1HDAC6HDAC1
Trifluoroacetic Acid SCHEMBL1058125 0.87 SGMS2 (0.42) TP53SGMS2SGMS1HDAC6HDAC1
Trifluoroacetic Acid SCHEMBL1063314 0.86 SGMS2 (0.41) TP53SGMS2SGMS1HDAC6HDAC1
SCHEMBL1060625 0.85 KDM4E (0.47) TP53SGMS2SGMS1HDAC6HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217176-B2 Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-10 US disclosed
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-06 US disclosed
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF SMO, NR1H2, NR1H4 TP53 3556/4885SGMS2 1431/4885SGMS1 1367/4885
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF SMO, NR1H2, NR1H4 TP53 3584/4885SGMS2 1493/4885SGMS1 1539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.